Administration of L-type VGCCs blockers resulted in multiple beneficial effects in animal MS models (see above), suggesting that CaV1.3 channels, perhaps in concert with CaV1.2 channels, contribute to tissue damage during MS. Here, CACNA1C is linked to myeloid sarcoma.